Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-001 in Advanced Malignancies
NCT07504263Phase 2Not yet recruiting
- Sponsor
- Recurv Pharma
- Start
- Apr 2026
- Primary completion
- Dec 2027
- Modality
- Nanoparticles, Small Molecules
01
Overview
A Phase 2 trial of RP-001 in solid tumor, pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), sponsored by Recurv Pharma. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
RP-001
03
Conditions
solid tumorpancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07504263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07504263.